Search­ing for a few great drugs, Bridge­Bio bags $135M to back a fresh slate of R&D bets

Bridge­Bio is all about shots on goal.

The last time I wrote a sto­ry about the com­pa­ny in April, CEO Neil Ku­mar had just es­tab­lished his 9th sub­sidiary op­er­a­tion to ex­plore a small mol­e­cule ther­a­py for transthyretin (TTR) amy­loi­do­sis. And now it’s lined up $135 mil­lion — more than it’s ever raised be­fore — to es­tab­lish up to 10 more of these R&D ef­forts.

Sig­nif­i­cant­ly, KKR came back in to co-lead the round, joined by new in­vestor Viking Glob­al In­vestors. Ex­ist­ing in­vestor Per­cep­tive Ad­vi­sors came back in, along­side a slate of new in­vestors: AIG, Ais­ling Cap­i­tal, Cor­morant Cap­i­tal and Janus Funds.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.